Gene expression of IL-6 and TNF-α in the rectal mucosa of patients with chronic idiopathic ulcerative colitis and controls;Expresión del gen de IL-6 y TNF-α en la mucosa rectal de pacientes con colitis ulcerosa crónica idiopática y controles

Revista de Gastroenterologia de Mexico

Volumn 74, Issue 4, 2009, Pages 334-340

  Fonseca Camarillo, G C ^a   Villeda Ramirez M A ^a   Sanchez Munoz F ^a   Barreto Zuniga R ^b   Dominguez Lopez A ^a   Uribe Esquivel, M ^a   Yamamoto Furusho, J K ^a  

^a Clínica de Enfermedad Inflamatoria Intestinal   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Gene expression; Interleukin 6; Mexico; Rectum; Tumor necrosis factor alpha; Ulcerative colitis

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTESTINE MUCOSA; MALE; METABOLISM; RECTUM; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; RECTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856701756     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390-400. (Pubitemid 351320847)
2. Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico. A single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol 2009;43:221-24.
3. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. (Pubitemid 47123518)
4. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterology 2007;13:5577-80. (Pubitemid 350031477)
5. Van Limbergen J, Russell RK, Nimmo ER, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55. (Pubitemid 46465916)
6. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signalling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006,17:451-61. (Pubitemid 44793118)
7. Sánchez-Muñoz F, Domínguez-López A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterology 2008;14:4280-8.
8. Matsumoto S, Tsuruta O. et al. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187-96.
9. Raddatz D, Bockemül M. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005;17:547-57. (Pubitemid 40592713)
10. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9.
11. Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 2005;100:1134-42. (Pubitemid 40769053)
12. Sawa Y, Oshitani N. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med 2003;11:175-179.